StockDrifts LogoStockDrifts

Osang Healthcare 036220

Company
오상헬스케어Osang Healthcare
Insiders
4
Buys
31
Total Value
₩2.3B ($1.6M)
Avg Return
-17.93%
Last Filing
2026-05-08

Osang Healthcare (036220) has 31 disclosed insider purchases and 1 disclosed disposals on record, filed by 4 distinct insiders. Together those filings cover ₩2.3B ($1.6M) in reported transaction value. The earliest filing StockDrifts holds for Osang Healthcare is dated 2024-03-13; the most recent is 2026-05-08. All of it is parsed from DART D001/D002 insider disclosures, the official disclosure system operated by the Financial Supervisory Service (Korea). Across these filings the average return since disclosure is -17.93%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

DateTypeSourceInsiderPositionSharesPrice at filingReturnValue
2026-05-08BUY자사주상여금
박미숙
Park Mi-sook
vice president500---
2026-05-08BUY자사주상여금
한정
limitation
moving150---
2026-04-01BUYMarket Buy
강철훈
Kang Cheol-hoon
CEO/President100₩8,830+15.4%₩883K ($613)
2026-01-12BUYMarket Buy
강철훈
Kang Cheol-hoon
CEO/President100₩11,000-7.4%₩1M ($764)
2026-01-06BUYMarket Buy
강철훈
Kang Cheol-hoon
CEO/President200₩11,530-11.6%₩2M ($2K)
2025-12-23BUYMarket Buy
강철훈
Kang Cheol-hoon
CEO/President100---
2025-12-22BUYMarket Buy
강철훈
Kang Cheol-hoon
CEO/President400---
2025-12-12BUYMarket Buy
강철훈
Kang Cheol-hoon
CEO/President100₩12,310-9.4%₩1M ($855)
2025-11-26BUYMarket Buy
강철훈
Kang Cheol-hoon
CEO/President100₩12,560-11.2%₩1M ($872)
2025-11-07BUYMarket Buy
강철훈
Kang Cheol-hoon
CEO/President100₩12,410-10.2%₩1M ($862)
2025-11-05BUYMarket Buy
강철훈
Kang Cheol-hoon
CEO/President100₩12,710-12.3%₩1M ($883)
2025-11-04BUYMarket Buy
강철훈
Kang Cheol-hoon
CEO/President100₩12,950-13.9%₩1M ($899)
2025-11-03BUYMarket Buy
강철훈
Kang Cheol-hoon
CEO/President200₩12,730-12.4%₩3M ($2K)
2025-10-28BUYMarket Buy
강철훈
Kang Cheol-hoon
CEO/President100₩13,680-18.5%₩1M ($950)
2025-05-28SELLMarket Sell
김주형
Joohyung Kim
moving-2.0K₩19,900+44.0%₩40M ($28K)
2025-04-28BUY자사주상여금
손병창
Son Byeongchang
Managing Director2.0K₩13,470-17.2%₩27M ($19K)
2025-04-28BUY자사주상여금
박미숙
Park Mi-sook
Managing Director500₩13,470-17.2%₩7M ($5K)
2025-03-25BUY자사주상여금
김주형
Joohyung Kim
moving2.0K₩14,000-20.4%₩28M ($19K)
2025-03-25BUY주식매수선택권
김주형
Joohyung Kim
moving10.0K₩14,000-20.4%₩140M ($97K)
2025-02-17BUYMarket Buy
오상자이엘
Oh Sangjaiel
-5.0K₩15,070-26.0%₩75M ($52K)
2025-02-14BUYMarket Buy
오상자이엘
Oh Sangjaiel
-10.0K₩15,090-26.1%₩151M ($105K)
2025-02-13BUYMarket Buy
오상자이엘
Oh Sangjaiel
-10.0K₩15,670-28.8%₩157M ($109K)
2025-02-12BUYMarket Buy
오상자이엘
Oh Sangjaiel
-10.0K₩15,870-29.7%₩159M ($110K)
2025-02-11BUYMarket Buy
오상자이엘
Oh Sangjaiel
-10.0K₩15,630-28.7%₩156M ($109K)
2025-02-10BUYMarket Buy
오상자이엘
Oh Sangjaiel
-10.0K₩15,640-28.7%₩156M ($109K)
2025-02-07BUYMarket Buy
오상자이엘
Oh Sangjaiel
-10.0K₩15,920-30.0%₩159M ($111K)
2025-02-06BUYMarket Buy
오상자이엘
Oh Sangjaiel
-10.0K₩15,570-28.4%₩156M ($108K)
2025-02-05BUYMarket Buy
오상자이엘
Oh Sangjaiel
-5.0K₩15,550-28.3%₩78M ($54K)
2025-02-04BUYMarket Buy
오상자이엘
Oh Sangjaiel
-8.0K₩15,490-28.0%₩124M ($86K)
2025-02-03BUYMarket Buy
오상자이엘
Oh Sangjaiel
-10.0K₩15,500-28.1%₩155M ($108K)
2025-01-31BUYMarket Buy
오상자이엘
Oh Sangjaiel
-11.4K₩14,820-24.8%₩169M ($117K)
2025-01-24BUYMarket Buy
오상자이엘
Oh Sangjaiel
-10.6K₩14,430-22.7%₩153M ($106K)
2025-01-24BUYMarket Buy
이종민
Jongmin Lee
Outside Director2.0K₩14,430-22.7%₩29M ($20K)
2025-01-23BUYMarket Buy
오상자이엘
Oh Sangjaiel
-10.0K₩15,410-27.6%₩154M ($107K)
2025-01-22BUYMarket Buy
오상자이엘
Oh Sangjaiel
-10.0K₩15,980-30.2%₩160M ($111K)
2024-09-27BUY자사주상여금
이의섭
Lee Eui-seop
vice president1.0K₩12,990-14.2%₩13M ($9K)
2024-09-27BUY자사주상여금
김주형
Joohyung Kim
moving6.0K₩12,990-14.2%₩78M ($54K)
2024-09-27BUY자사주상여금
손병창
Son Byeongchang
Managing Director2.0K₩12,990-14.2%₩27M ($18K)
2024-09-10BUYMarket Buy
강철훈
Kang Cheol-hoon
CEO/President227₩12,990-14.2%₩3M ($2K)
2024-09-09BUYMarket Buy
강철훈
Kang Cheol-hoon
CEO/President1.0K₩13,090-14.8%₩13M ($9K)
2024-06-20BUYMarket Buy
이종민
Jongmin Lee
Outside Director2.0K₩14,420-22.7%₩29M ($20K)
2024-03-29BUY신규선임
이종민
Jongmin Lee
Outside Director3₩19,970-44.2%₩60K ($42)
2024-03-26BUY주식매수선택권
홍승억
Seung-Eok Hong
CEO40.0K₩21,150-47.3%₩846M ($588K)
2024-03-26BUY주식매수선택권
이의섭
Lee Eui-seop
vice president10.0K₩21,150-47.3%₩212M ($147K)
2024-03-26BUY주식매수선택권
손병창
Son Byeongchang
Managing Director10.0K₩21,150-47.3%₩212M ($147K)
2024-03-26BUY주식매수선택권
김주형
Joohyung Kim
moving5.0K₩21,150-47.3%₩106M ($73K)
2024-03-13BUYPROGRAM
유병열
Yoo Byung-yeol
Internal director50.0K₩29,350-62.0%₩1.5B ($1.0M)
2024-03-13BUYPROGRAM
이동현
Donghyun Lee
Internal director723.6K₩29,350-62.0%₩21.2B ($14.7M)
2024-03-13BUYPROGRAM
이의섭
Lee Eui-seop
vice president15.0K₩29,350-62.0%₩440M ($306K)
2024-03-13BUYPROGRAM
홍승억
Seung-Eok Hong
CEO50.0K₩29,350-62.0%₩1.5B ($1.0M)

Showing the 50 most recent of 56 filings.

Frequently asked questions

Who has been buying Osang Healthcare stock?
4 distinct insiders have filed 31 disclosed insider purchases in Osang Healthcare (036220), most recently on 2026-05-08. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does Osang Healthcare have?
Osang Healthcare has 31 buy-side and 1 sell-side disclosures on record, covering ₩2.3B ($1.6M) in total reported value, spanning 2024-03-13 to 2026-05-08.
Where does StockDrifts get Osang Healthcare insider data?
From DART D001/D002 insider disclosures — the official filing system run by the Financial Supervisory Service (Korea). StockDrifts parses each disclosure and matches it to daily price history; the original filings remain available directly from DART.
Do insider buys in Korean stocks predict returns?
Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean DART filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Source filings

Every trade listed above is disclosed in DART D001/D002 insider disclosures, filed with the Financial Supervisory Service (Korea). View the original DART filings for Osang Healthcare. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.